Cancer-related fatigue and associated disability in post-treatment cancer survivors
the ONA take:
Cancer-related fatigue (CRF) is the most common symptom for patients with cancer. However, data on its prevalence in the posttreatment period is limited.
Using a self-administered mail-based questionnaire, these researchers sought to measure occurrence of CRF in three cohorts (16 to 18 months posttreatment, 2 to 3 years posttreatment, and 5 to 6 years posttreatment) of disease-free survivors of breast, prostate, or colorectal cancer.
The study generated a 63% response rate (2,294 questionnaire packages were returned). Twenty-nine percent of respondents reported significant fatigue, although fatigue levels did not differ between time cohorts.
Reports of fatigue were significantly higher in survivors of breast or colorectal cancer compared with survivors of prostate cancer.
The researchers conclude that approximately one-third of cancer survivors experience fatigue for up to 6 years after treatment. Clinicians should be aware that fatigue can be a chronic condition, and should routinely assess for it.
Cancer-related fatigue is the most common symptom for patients with cancer.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|